Soluble Epoxide Hydrolase Inhibitors: A New Frontier in Inflammation and Cancer Prevention

Soluble Epoxide Hydrolase Inhibitors: Chronic inflammation has long been recognized as a driving force behind many cancers, particularly in conditions such as ulcerative colitis and inflammatory bowel disease. Recent research highlights soluble epoxide hydrolase (sEH) as a key molecular link between unresolved inflammation and carcinogenesis. By degrading epoxyeicosatrienoic acids (EETs)—lipid mediators with strong anti-inflammatory and tissue-protective properties—sEH undermines the body’s natural defense against inflammation. Inhibitors of sEH (sEHIs) offer a promising therapeutic approach by stabilizing EETs, activating anti-inflammatory pathways such as PPAR-γ, and suppressing pro-inflammatory signals like NF-κB. Preclinical studies demonstrate that sEHIs reduce acute inflammation, protect against colitis, and even prevent the progression from chronic inflammation to cancer. With favorable safety profiles and biomarker-driven strategies for monitoring efficacy, sEH inhibition represents a new frontier in anti-inflammatory therapy and cancer prevention. This article reviews the role of EETs and sEH in inflammation, explores the mechanisms of sEH inhibition, and considers the future clinical potential of this novel therapeutic class.

Introduction: Inflammation, Cancer, and the Missing Link

For decades, scientists have recognized that chronic inflammation is not just a symptom of disease but also a powerful driver of cancer development. Unlike acute inflammation, which serves as a rapid defense against injury or infection, chronic inflammation lingers for months or even years. This persistent activation of the immune system floods tissues with cytokines, growth factors, and reactive oxygen species. Over time, these inflammatory signals create a hostile microenvironment—damaging DNA, fueling abnormal cell proliferation, and weakening the body’s ability to control rogue cells.

The clinical evidence is striking. Patients with ulcerative colitis (UC) or Crohn’s disease, two major forms of inflammatory bowel disease (IBD), have a significantly higher risk of developing colorectal cancer compared with the general population. The longer the duration of inflammation, the greater the risk, suggesting a direct and cumulative effect of unresolved immune activity on cancer initiation. Similar trends are seen in other chronic inflammatory conditions such as hepatitis, gastritis caused by Helicobacter pylori, and chronic pancreatitis. In each case, the constant inflammatory stress accelerates the journey from healthy tissue to dysplasia and ultimately to malignancy.

Yet, the molecular players linking inflammation to cancer progression are still being uncovered. Among these, enzymes involved in lipid mediator metabolism have emerged as critical regulators of the inflammatory response. Lipid mediators, derived from arachidonic acid and related fatty acids, orchestrate immune cell behavior, vascular tone, and tissue repair. When balanced, they resolve inflammation and restore homeostasis. But when disrupted, they sustain the very processes that push tissues toward disease.

One such enzyme, soluble epoxide hydrolase (sEH), has recently captured attention as a potential “missing link” between inflammation and carcinogenesis. By degrading epoxyeicosatrienoic acids (EETs)—lipid molecules with potent anti-inflammatory and pro-resolving properties—sEH effectively silences one of the body’s natural defense mechanisms against chronic inflammation. Early research suggests that heightened sEH activity not only worsens inflammatory disease but also lays the groundwork for cancer to develop in vulnerable tissues.

As researchers unravel this pathway, the possibility emerges that targeting sEH may offer a novel strategy: not merely treating inflammation, but breaking the chain that connects inflammation to cancer itself. This perspective opens an exciting frontier in both cancer prevention and therapy.

Meet the Mediators: EETs, sEH, and the Body’s Natural Defenses

When we think about inflammation, enzymes like cyclooxygenase (COX) and lipoxygenase (LOX) often dominate the discussion. These are the pathways that generate prostaglandins and leukotrienes—molecules long recognized for amplifying pain, swelling, and fever. Yet, there is another branch of arachidonic acid metabolism that plays a more subtle but critical role in maintaining balance: the cytochrome P450 epoxygenase pathway.

Through this pathway, arachidonic acid is converted into a group of bioactive lipids known as epoxyeicosatrienoic acids (EETs). Unlike prostaglandins and leukotrienes, EETs are widely considered pro-resolving mediators. They help blood vessels relax, limit the adhesion of white blood cells to vessel walls, reduce cytokine production, and protect tissues from excessive oxidative stress. In essence, EETs act as a molecular brake on runaway inflammation.

Unfortunately, this brake is easily disabled by the enzyme soluble epoxide hydrolase (sEH). Found in many tissues including the liver, kidney, intestine, and vascular endothelium, sEH rapidly converts EETs into their less active diols, called dihydroxyeicosatrienoic acids (DHETs). While EETs are anti-inflammatory and cytoprotective, DHETs lack most of these beneficial effects. The result is a tipping of the scale toward chronic inflammation.

The impact of sEH is not confined to a single organ system. For instance, in the cardiovascular system, high sEH activity can lead to endothelial dysfunction and hypertension. In the gastrointestinal tract, it contributes to uncontrolled inflammatory signaling, fueling diseases like ulcerative colitis. In the central nervous system, it has been linked to neuroinflammatory conditions. Across these contexts, the unifying theme is that sEH undermines the body’s own natural defenses by depleting EETs.

Figure 1. Multiple pathways of inflammation inhibition through targeting sEH.

This makes the enzyme an attractive therapeutic target. By inhibiting sEH, researchers aim to stabilize endogenous EET levels, thereby restoring their protective influence. Importantly, such an approach does not block inflammation outright—like COX inhibitors do—but instead preserves the molecules that guide the body back to balance. This distinction may be the key to developing safer anti-inflammatory therapies that work with, rather than against, the body’s natural regulatory systems.

Blocking the Culprit: How sEH Inhibitors Work

The discovery of soluble epoxide hydrolase (sEH) as a pivotal enzyme in the breakdown of epoxyeicosatrienoic acids (EETs) has opened the door to a novel class of therapeutic agents: sEH inhibitors (sEHIs). Rather than suppressing inflammatory pathways directly, these molecules work by preserving the body’s own anti-inflammatory lipids. This approach represents a paradigm shift, moving from blunt inhibition toward restoring balance in lipid mediator signaling.

At the molecular level, sEHIs prevent the conversion of EETs into their inactive diol forms, dihydroxyeicosatrienoic acids (DHETs). As a result, endogenous EETs accumulate and exert prolonged protective effects. These include reducing leukocyte adhesion, improving vascular function, and dampening pro-inflammatory cytokine production. In essence, sEHIs amplify the body’s natural defense system against uncontrolled inflammation.

One of the most fascinating aspects of sEH inhibition is its multi-node impact on cellular signaling. Elevated EET levels activate peroxisome proliferator-activated receptor gamma (PPAR-γ), a transcription factor that promotes anti-inflammatory gene expression and supports metabolic health. Simultaneously, EETs suppress nuclear factor kappa B (NF-κB), a central regulator of pro-inflammatory genes, including those coding for cytokines, inducible nitric oxide synthase (iNOS), and adhesion molecules such as VCAM-1. Through this dual mechanism, sEHIs not only curb inflammation but also limit the cellular stress responses that often precede tissue damage and carcinogenesis.

Another advantage of sEH inhibition lies in its potential synergy with existing drugs. Preclinical studies suggest that combining sEHIs with nonsteroidal anti-inflammatory drugs (NSAIDs) enhances therapeutic efficacy while reducing gastrointestinal and cardiovascular side effects typically associated with high-dose NSAID use. This synergistic action arises because NSAIDs block the cyclooxygenase (COX) pathway, while sEHIs stabilize EETs, together reshaping the inflammatory landscape.

Equally important is the development of biomarkers to monitor sEHI activity. The epoxide-to-diol ratio in plasma has emerged as a reliable readout of drug efficacy, allowing researchers to track how well inhibitors stabilize EETs in vivo. This biomarker-driven approach could accelerate the translation of sEHIs from preclinical research to clinical trials.

By targeting sEH, scientists are not merely blocking a pathway—they are unlocking the full therapeutic potential of endogenous EETs. This strategy offers a unique way to reduce inflammation, protect tissues, and perhaps even prevent cancers rooted in chronic inflammatory states.

Evidence from Bench to Bedside

The promise of soluble epoxide hydrolase inhibitors (sEHIs) extends beyond theory—numerous preclinical and translational studies provide compelling evidence for their role in controlling inflammation and reducing cancer risk. By stabilizing epoxyeicosatrienoic acids (EETs), sEHIs consistently demonstrate protective effects across a wide spectrum of disease models, bridging the gap between molecular insight and potential clinical application.

In models of acute inflammation, sEHIs such as AUDA-nBE have been shown to reduce nitric oxide production, inflammatory cytokine release, and leukocyte infiltration. For example, in lipopolysaccharide (LPS)-induced sepsis models, animals treated with sEHIs not only experienced dampened inflammatory responses but also exhibited significantly improved survival rates. Similarly, in smoke-exposed rodent lungs, sEH inhibition reduced the influx of neutrophils, macrophages, and lymphocytes—underscoring their broad anti-inflammatory potential.

Perhaps the most striking evidence comes from gastrointestinal disease models, particularly ulcerative colitis and colitis-associated cancer. In dextran sulfate sodium (DSS)-induced colitis, sEHIs prevented ulcer formation, restored mucosal integrity, and decreased histological markers of inflammation. In genetically susceptible IL-10 knockout mice, long-term sEH inhibition markedly reduced the progression from chronic colitis to dysplasia and carcinoma. These findings suggest that sEHIs not only alleviate inflammation but also interrupt the progression from inflammation to malignancy, a critical link in cancer prevention research.

Human data, while still emerging, are highly suggestive. Studies examining colon tissue from ulcerative colitis patients reveal a progressive increase in sEH expression: low in healthy controls, higher in UC, and dramatically elevated in dysplasia and colorectal carcinoma. This stepwise pattern of sEH upregulation reinforces the enzyme’s role in inflammation-driven carcinogenesis and points to its potential as both a biomarker and therapeutic target.

Adding to their translational value, sEHIs exhibit favorable safety profiles in preclinical toxicology studies and show promise in combination with existing therapies. For example, pairing sEHIs with nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to enhance efficacy while potentially lowering the risks of gastrointestinal and cardiovascular side effects.

Together, these findings highlight sEH inhibition as a bench-to-bedside strategy: starting with mechanistic validation in cells, moving through robust animal studies, and culminating in human observations that set the stage for clinical trials. The trajectory suggests that sEHIs could emerge as a new class of anti-inflammatory agents with applications in cancer prevention, gastrointestinal disease, and beyond.

Future Outlook: From Research to Real-World Therapies

The growing body of research around soluble epoxide hydrolase (sEH) and its inhibitors (sEHIs) paints an optimistic picture for the future of inflammation-targeted therapies. Unlike traditional anti-inflammatory drugs, which often work by bluntly blocking pathways such as cyclooxygenase (COX), sEHIs function by stabilizing the body’s natural pro-resolving lipids—the epoxyeicosatrienoic acids (EETs). This nuanced approach is designed not to shut down inflammation entirely, but to promote balance and resolution, potentially reducing the side effects seen with conventional therapies.